Aclaris Therapeutics, Inc. (ACRS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 1,777 | 1,455 | 4,346 | 2,766 |
| Research and development | 11,449 | 11,584 | 5,956 | 8,759 |
| General and administrative | 5,386 | 6,139 | 5,653 | 4,752 |
| Cost of revenue | 515 | 506 | 654 | 624 |
| Revaluation of contingent consideration | 1,500 | 300 | 800 | 200 |
| Licensing | 1,335 | 1,010 | 1,754 | 1,285 |
| Total costs and expenses | 20,185 | 19,539 | 14,817 | 15,620 |
| Loss from operations | -18,408 | -18,084 | -10,471 | -12,854 |
| Non-cash royalty income | 961 | 833 | 894 | - |
| Interest income | 2,018 | 2,166 | 1,991 | - |
| Total other income | 2,979 | 2,999 | 2,885 | - |
| Other nonoperating income (expense) | - | - | - | 1,868 |
| Net loss | -15,429 | -15,085 | -7,586 | -10,986 |
| Unrealized gain (loss) on marketable securities, net of tax of 0 | 48 | 337 | 890 | -99 |
| Total other comprehensive income (loss) | 48 | 337 | 890 | -99 |
| Comprehensive loss | -15,381 | -14,748 | -6,696 | -11,085 |
| Earnings per share, basic | -0.13 | -0.12 | -0.11 | -0.15 |
| Earnings per share, diluted | -0.13 | -0.12 | -0.11 | -0.15 |
| Weighted average number of shares outstanding, basic | 122,580,967 | 122,390,303 | 71,381,731 | 71,291,400 |
| Weighted average number of shares outstanding, diluted | 122,580,967 | 122,390,303 | 71,381,731 | 71,291,400 |